# 1. Financial Performance ## A. Key Figures * Consolidated Revenue: **₹2,245 Cr** Q3 FY'26 (~+6.5%) · **₹7,258 Cr** 9M FY'26 (+8.44%) * EBITDA Margin: 26.09% stand-alone Q3 FY'26 (+81% YoY) · 22.5% consolidated Q3 FY'26 (+28% YoY) · 20.79% 9M FY'26 (+61% YoY) * Material Cost-to-Sales Ratio: 24% stand-alone Q3 FY'26 · 25.37% 9M FY'26 (vs. 28.73% prior year) * **Land Sale & Cash:** **₹275 Cr** proceeds · **₹181 Cr** used for EU fine · **>₹250 Cr** cash reserves post-settlement ## B. Revenue Growth * **Resilient Top-Line Trajectory:** 9-month revenue posted robust growth despite a modest sequential decline in Q3, indicating sustained underlying demand and scaling momentum. ## C. EBITDA Margins * **Sharp Margin Expansion:** Significant YoY and 9-month EBITDA margin improvement driven primarily by **favorable product mix**, with high-margin domestic chronic and branded segments outpacing lower-margin acute and antimalarial businesses. * **Operational Leverage:** Material cost-to-sales ratio improved sharply by **36 percentage points** over 9M, with further **64 percentage point improvement** in Q3 alone, signaling strong cost control and efficiency gains. * **Segmental Strength:** Consolidated margin gains exceeded stand-alone performance due to outsized contributions from **Ipca’s business** and **Trophic Wellness’ nutraceutical segment**. * **Unichem Margin Pressure:** Unichem’s EBITDA margin at **~8%** remains constrained by lower capacity utilization and loss of high-volume U.S. contracts, though offset by broader portfolio strength. ## D. Cash Flow * **Strategic Capital Allocation:** Land sale generated substantial liquidity; after settling legacy EU fine, company retains **over ₹250 Cr in cash**, enhancing financial flexibility for future investments. --- # 2. Product & Therapy Performance ## A. Key Figures * **Domestic Formulations Growth:** **~12%** Q3 FY26 (+300 bps vs. IPM) * **Export Formulations:** **~17%** Q3 growth · **INR1,477 Cr** 9M revenue (+6%) * **API Revenue:** **~INR317 Cr** Q3 (flat) · **INR1,051 Cr** 9M revenue (+14%) ## B. Domestic Formulations Performance * **Outperformance vs. Market:** Domestic business continues to grow above IPM, maintaining **top 5–10 ranking** in growth despite sector-wide moderation. * **Therapeutic Strength in Chronic Care:** Chronic segment outpaced market with **15% growth**, led by **CNS (+19%)**, **derma (+22%)**, and **neurology (+17%)**, signaling successful portfolio momentum. * **Pain Management Dominance:** Pain segment remains the largest revenue contributor with **over 50% share**, growing at **13%** in Q3. * **Cardiovascular Recovery:** CV business rebounded with **16% growth** after reorganization-driven softness at fiscal start. * **Diabetes & Acute Trends:** Diabetes delivered **14% growth**, while acute segment lagged with **4% growth** against a 9% market. ## C. Export Generics * **Robust Export Growth:** Formulations exports posted **strong double-digit growth** in Q3, supported by volume expansion and new market penetration. ## D. API Business * **Domestic API Decline:** Domestic API volumes down YoY due to **sharp drop in antimalarials** and lower **Shirasho peptide** output; no broader pricing or demand issues noted. * **Growth Outlook:** API segment expected to grow at a **slightly lower rate** than generics and branded formulations, with domestic API projected at **10–12%** annual growth. --- # 3. Geography & Market Mix ## A. Key Figures * **B. S. Business (Combined):** ₹395 Cr Q3 FY26 (+~17%) · ₹339 Cr Q3 FY25 * **West Africa Sales Growth:** +41% (9M) · +69% (Q3) * **Unichem U.S. Revenue:** -2% (QoQ) · -2% (FY-to-date ex-Ipca) * **Ipca U.S. Product Revenue:** ₹1 Cr (9M, 5 products) ## B. U.S. Business * **Mixed U.S. Performance:** Combined U.S. business showed strong double-digit growth, driven by Ipca’s own portfolio and former Bayshore products, despite Unichem’s market share losses in key molecules. * **Market Share Reset:** Unichem faced headwinds from loss of high-volume, low-margin U.S. businesses impacting overhead recovery, with recovery expected in 2–3 quarters at lower prices. * **Growth Pipeline:** 4–5 additional IPCA molecules set to launch in U.S. over next 6–12 months; 5 backward-integrated products already gaining traction with **25%+ market share**. * **Revenue Reinstatement:** Return of Ipca’s former ₹300 Cr U.S. business adds structural growth tailwind, partially offsetting current Unichem softness. ## C. European Markets * **Stable Core, Selective Recovery:** European operations remain steady with strong margins in Australia, Canada, and New Zealand; improving performance in previously challenged low-margin Scandinavian markets. * **Limited Major Market Exposure:** No presence in Germany, France, or Italy; maintains solid footprint in Spain and U.K., where management confirms no operational issues. ## D. Rest of World * **West Africa Outperformance:** Branded promotional business surged with strong double-digit momentum, led by **69% Q3 growth** in French-speaking Africa. * **India Market Position:** IPCA holds stable **8% market share** and **16th rank** nationally (IQVIA, MAT Dec-25), signaling resilience in domestic generics. * **Unichem Growth Levers:** Geographic mix remains U.S.-dominant (~two-thirds), with margin and growth recovery expected over next 2–3 years from pending European and ROW product approvals. --- # 4. R&D & Pipeline Progress ## A. Key Figures * **B. S. Filings:** **4** in current year · **>30** total filings with **8–10** approvals pending * **Product Launches:** **5** commercialized · **5–7** expected in U.S. over next **12–15 months** * **Pipeline Scale:** **35** total registrations · Target of **5–6** new U.S. launches annually ## B. U.S. Filings * **Pipeline Acceleration:** R&D output is rising, driving increased filing activity in generics and ROW markets, signaling stronger future growth potential. * **Strategic Expansion:** In-licensing is being actively pursued to augment the generic launch pipeline and complement internal manufacturing capabilities. * **Regulatory Dependency:** Commercialization timelines remain subject to regulatory approval schedules, limiting near-term visibility despite a robust pipeline. --- # 5. Manufacturing & Utilization ## A. Key Figures * **Capital Expenditure:** **₹50 Cr** allocated for ongoing solar energy project ## B. Capacity Use * **Strategic Growth Levers:** Focus on integrated manufacturing, U.S. and Unichem optimization, and capability expansion in biosimilars, injectables, and hormones to drive market share recovery. * **C. S. Market Recovery Plan:** Targeted launch of **4–5 new molecules** and corrective actions on **2–3 major lost molecules** amid competitive pricing pressures. * **Margin Potential:** High underlying manufacturing capacity provides structural leverage, with margin expansion expected from improved utilization, particularly via European market entry. ## C. Green Energy * **Capital Discipline:** No major capex planned outside of current green initiatives; solar project supports sustainability goals with minimal financial outlay. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **B. S. Contract Durations:** **3, 6, or 12 months** (no fixed term) * **European Registration Timeline:** **1 to 2 years** for approval * **U.K. Price Recovery:** **30% to 40%** increase in prices over past month ## B. U.S. Competition * **Flexible Contracting:** U.S. agreements feature variable durations, enabling adaptability but implying recurring renegotiation risk. ## C. European Approvals * **Long Lead Times:** European market entry is structurally delayed by **1- to 2-year** registration timelines, constraining near-term scaling despite active filings. ## D. U.K. Pricing Volatility * **Sharp Rebound After Collapse:** Following a period of loss-making sales in a saturated "blood bath" market, U.K. pricing has seen **rapid normalization** with strong double-digit recovery. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **8%–10%** Unichem long-term · **10%–11%** overall company * **B. S. Business Growth (Post-Recovery):** **7%–8%** annual, driven by **4–5 new molecule launches** in 2–3 years * **EBITDA Margin Trajectory:** **~15%** current, targeted **20%** in 2–3 years (~**300 bps improvement**) ## B. Revenue Forecast * **Global Expansion Strategy:** Regulatory greenlights secured from **C. S. FDA, U.K. MHRA, and European authorities**, enabling execution across all global markets. * **Growth Nuance:** 8%–10% Unichem growth excludes **Ipca’s U.S. sales contribution**; reflects stand-alone U.S. division recovery and new product launches. * **Cautious Near-Term Tone:** Outlook tempered by **institutional business uncertainties**, with full segment guidance delayed until post-March budget finalization. ## C. Margin Expansion * **Margin Recovery Path:** EBITDA margin expansion hinges on